Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SNY vs MAIA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNY Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

SNY Overall Winner 6-Pillar Tally: SNY 4 – 1 MAIA (1 Tie) Matrix Metrics: SNY 8 – 2 MAIA

As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNY carries a Unified Composite Score of 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin), whereas MAIA carries 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both SNY (40.3/100 SELL) and MAIA (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNY vs MAIA
SNY NASDAQ Head-to-Head Winner
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Pharmaceutical Preparations
$46.52
+1.0% 1D
Market Cap $110.6B
TTM Revenue $30.1B
Forward P/E 8.6x
Beta / 30D Vol 0.20β · 26% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 32.0 Fund 43.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.6% over 20 days), RSI 58
RSI-14: 57.5 · SMA20: $46.15 · SMA50: $43.08
MAIA NYSE American
MAIA Biotechnology, Inc.
Pharmaceutical Preparations
$1.11
-2.63% 1D
Market Cap $68.5M
TTM Revenue N/A
Forward P/E 1.2x
Beta / 30D Vol 1.65β · 108% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 40.0 Fund 38.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.8 · SMA20: $1.11 · SMA50: $1.17

6-Pillar Scorecard Institutional Category Breakdown (SNY 4 – 1 MAIA)

Columns: Metric · SNY · MAIA
1. Valuation Multiples MAIA
Forward P/E 8.6x 1.2x
Trailing P/E 22.9x 1.2x
PEG Ratio 2.90x N/M
EV / Revenue 3.7x N/M
2. Growth & Scale SNY
Revenue Growth (YoY) +15.7% +0.0%
Earnings Growth (YoY) +9.4% +0.0%
TTM Revenue (USD) $30.1B N/A
Market Cap $110.6B $68.5M
3. Profitability & Quality SNY
Gross Margin 74.3% N/A
Operating Margin 22.3% 0.0%
Net Profit Margin 8.2% 0.0%
Return on Equity (ROE) 5.7% -341.5%
4. Balance Sheet & Cash Flow SNY
Cash Generation (TTM) $8.72B EBITDA -$20M
Cash Flow Margin 29.0% EBITDA Mgn N/A
Net Cash / Leverage $34.11 Book/Sh · 5.7% ROE $0.24 Book/Sh · -341.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 22.0% (43rd %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNY
OpEx & R&D Intensity 52.0% of Rev ($15.6B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNY (8) vs MAIA (2)
Institutional Metric SNY MAIA Criterion Row Edge
Market Capitalization
Scale
$110.6B $68.5M Larger Scale SNY
Trailing P/E Ratio
Valuation
22.9x 1.2x Lower Multiple MAIA
Forward P/E Ratio
Valuation
8.6x 1.2x Lower Multiple MAIA
Revenue Growth (YoY)
Growth
+15.7% +0.0% Higher Growth SNY
Operating Margin (TTM)
Profitability
22.3% 0.0% Higher Margin SNY
Net Profit Margin
Profitability
8.2% 0.0% Higher Margin SNY
Return on Equity (ROE)
Capital Efficiency
5.7% -341.5% Higher ROE SNY
52-Week Range Position
Momentum
65% ($39–$51) 10% ($1–$3) Stronger Trend SNY
Beta / 30D Volatility
Risk Regime
0.20β · 26% Vol 1.65β · 108% Vol Lower Realized Risk SNY
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 37.6 / 100 (SELL) Higher Composite SNY
Trailing 12M Revenue (USD)
Operating Scale
$30.1B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.90x PEG · 3.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.72B EBITDA ($34.11 Book/Sh · 5.7% ROE) -$20M ($0.24 Book/Sh · -341.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNY +12.64 pp
SNY: +10.87% · MAIA: -1.77%
3M Horizon SNY +19.6 pp
SNY: +1.82% · MAIA: -17.78%
6M Horizon SNY +18.31 pp
SNY: +5.03% · MAIA: -13.28%
1Y Horizon MAIA +26.77 pp
SNY: -6.12% · MAIA: +20.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNY vs MAIA. Trailing 12-month operating profitability (SNY 22.3% vs MAIA 0.0%) and valuation multiples (SNY 8.6x vs MAIA 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.

SNY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30.1B
Gross Margin74.3%
Op. Margin22.3%
ROE / Fwd P/E5.7% · 8.6x
MAIA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-341.5% · 1.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.0%
IV Percentile 43rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MAIA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MAIA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNY Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $110.6B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment 52.0% of Rev ($15.6B)
90D Engineering Disclosures 0 Published
MAIA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $68.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SNY vs MAIA Key Questions & Quantitative Answers

As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNY carries a Unified Composite Score of 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin), whereas MAIA carries 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both SNY (40.3/100 SELL) and MAIA (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SNY leads the Growth & Scale pillar: SNY posts +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.1B TTM revenue (74.3% gross margin, 22.3% operating margin), compared with MAIA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SNY generates $30.1B in USD-normalized revenue versus N/A for MAIA. In operating R&D and SG&A reinvestment, SNY deploys 52.0% of Rev ($15.6B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MAIA.

MAIA screens cheaper on headline valuation multiples. SNY trades at 8.6x Forward P/E, 22.9x Trailing P/E, 2.90x PEG, and 3.7x EV/Revenue (29.0% EBITDA margin), whereas MAIA trades at 1.2x Forward P/E, 1.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNY (5.7% ROE) versus MAIA (-341.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.20β · 26% Vol realized risk). By comparison, MAIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.